Phase 3 Trial of Selpercatinib in Advanced RET-Mutant Medullary Thyroid Cancer.

MLA

Hadoux, J., et al. “Phase 3 Trial of Selpercatinib in Advanced RET-Mutant Medullary Thyroid Cancer.” New England Journal of Medicine, vol. 389, no. 20, Nov. 2023, pp. 1851–61. EBSCOhost, https://doi.org/10.1056/NEJMoa2309719.

APA

Hadoux, J., Elisei, R., Brose, M. S., Hoff, A. O., Robinson, B. G., Gao, M., Jarzab, B., Isaev, P., Kopeckova, K., Wadsley, J., Fohrer, D., Keam, B., Bardet, S., Sherman, E. J., Tahara, M., Hu, M. I., Singh, R., Lin, Y., Soldatenkova, V., & Wright, J. (2023). Phase 3 Trial of Selpercatinib in Advanced RET-Mutant Medullary Thyroid Cancer. New England Journal of Medicine, 389(20), 1851–1861. https://doi.org/10.1056/NEJMoa2309719

Chicago

Hadoux, J., R. Elisei, M. S. Brose, A. O. Hoff, B. G. Robinson, M. Gao, B. Jarzab, et al. 2023. “Phase 3 Trial of Selpercatinib in Advanced RET-Mutant Medullary Thyroid Cancer.” New England Journal of Medicine 389 (20): 1851–61. doi:10.1056/NEJMoa2309719.